Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROMIST vs MINITRAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing c GMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing c GMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.
Acute angina pectoris,Prophylaxis of angina pectoris,Acute coronary syndrome (off-label),Heart failure with preserved ejection fraction (off-label),Anal fissure (off-label)
Acute angina pectoris,Prophylaxis of angina pectoris (prior to activities that may provoke an attack),Chronic angina (off-label: long-term prophylaxis),Heart failure associated with acute myocardial infarction (off-label)
1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.
Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.
2–3 minutes for nitroglycerin; rapid metabolism results in short terminal half-life. Clinically, effects dissipate within 30 minutes of discontinuation.
Terminal half-life is approximately 1-4 minutes for nitroglycerin; clinical effect duration is longer due to tissue distribution.
Primarily hepatic via glutathione S-transferases (GST) and possibly cytochrome P450 (CYP3A4) to inactive metabolites.
Rapidly metabolized in the liver by glutathione-organic nitrate reductase, with minor contributions from vascular wall and RBC metabolism. Metabolites include 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate.
Renal excretion of inactive metabolites accounts for >80% of elimination; biliary/fecal excretion is minimal (<15%).
Primarily renal excretion of inactive metabolites; less than 1% excreted unchanged. Biliary/fecal elimination is minimal.
Approximately 60% bound to plasma proteins (albumin).
Approximately 60% bound to plasma proteins (albumin).
3.3 L/kg; large Vd indicates extensive tissue distribution, especially to vascular smooth muscle.
Vd is about 3 L/kg, indicating extensive tissue distribution.
Sublingual: ~40% (due to first-pass metabolism); transdermal: variable (~10–30%); intravenous: 100%.
Transdermal: approximately 70-80% of the dose reaches systemic circulation.
No dose adjustment required for renal impairment.
No specific dose adjustment required for renal impairment. However, patients with severe renal insufficiency (Cr Cl <30 m L/min) may have increased risk of adverse effects; monitor closely.
Use with caution in severe hepatic impairment (Child-Pugh C); consider dose reduction due to increased bioavailability.
No specific dose adjustment recommended for Child-Pugh A or B. For Child-Pugh C (severe hepatic impairment), consider reducing dose due to reduced metabolism and increased risk of hypotension; use with caution.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Safety and effectiveness in pediatric patients have not been established. Use only under expert guidance. Typical initial dose: 0.1-0.2 mg/hour transdermally, titrated cautiously based on clinical response and tolerance.
Initiate with lower doses (e.g., 1 spray = 0.4 mg) due to increased sensitivity and higher risk of hypotension.
Elderly patients may be more sensitive to the hypotensive effects. Start at the lower end of dosing range (0.2 mg/hour) and titrate slowly. Monitor blood pressure and heart rate regularly.
None.
Do not use MINITRAN in patients taking phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) as this can cause severe hypotension. Additionally, MINITRAN should not be used in patients with early myocardial infarction or severe anemia.
Hypotension,Hypovolemia,Increased intracranial pressure,Hypertrophic cardiomyopathy,Severe anemia,Tolerance with continuous use,Contraindicated use with phosphodiesterase-5 inhibitors (e.g., sildenafil)
Hypotension; paradoxical bradycardia; tolerance (need for nitrate-free interval); exacerbation of angina with abrupt discontinuation; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypersensitivity to nitroglycerin,Severe hypotension (SBP <90 mm Hg),Cardiac tamponade,Constrictive pericarditis,Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil),Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Severe anemia
Concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe anemia; increased intracranial pressure (e.g., head trauma, cerebral hemorrhage); acute circulatory failure; hypersensitivity to nitrates.
Avoid alcohol consumption as it may enhance the hypotensive effects of nitroglycerin. No specific food restrictions, but a high-fat meal may delay absorption if taken orally; however, Nitromist is a sublingual spray, so food interactions are minimal.
Concurrent use of alcohol can cause vasodilation and hypotension. Limit or avoid alcohol. No specific food restrictions.
FDA Pregnancy Category X. Nitroglycerin is contraindicated in pregnancy due to risk of fetal bradycardia and hypotension. First trimester: Risk cannot be ruled out; use only if clearly needed. Second and third trimesters: Increased risk of maternal hypotension leading to decreased placental perfusion. Not recommended.
Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trimesters: risk of fetal bradycardia, hypotension, and decreased placental perfusion.
Nitroglycerin is excreted into breast milk in small amounts; M/P ratio is approximately 0.55. American Academy of Pediatrics considers it compatible with breastfeeding. However, use caution in nursing mothers due to potential for infant hypotension.
Likely excreted in breast milk. M/P ratio not established. Use with caution; monitor infant for hypotension.
Standard dosing may be used but with caution due to increased plasma volume in pregnancy potentially altering pharmacokinetics. No specific dose adjustments recommended; start at lowest effective dose and titrate based on maternal response and fetal status.
No specific dose adjustments recommended, but use lowest effective dose due to potential for hypotension and decreased placental perfusion.
Nitromist (nitroglycerin lingual spray) is indicated for acute relief of angina pectoris. Onset of action is 1-3 minutes. Administer 1-2 sprays onto or under the tongue at the first sign of an attack; may repeat every 5 minutes up to 3 doses in 15 minutes. Do not shake canister. Avoid use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Hypotension, reflex tachycardia, and headache are common. Tolerance may develop with frequent use; a nitrate-free interval of 10-12 hours can minimize tolerance.
MINITRAN (nitroglycerin transdermal) is used for angina prophylaxis, not acute attacks. Apply to hairless area, rotate sites, and remove for 12-14 hours daily to prevent tolerance. If headache occurs, reduce dose or use acetaminophen. Do not discontinue abruptly to avoid rebound ischemia.
Use one or two sprays under or on the tongue at the first sign of chest pain; do not swallow. If no relief after 5 minutes, call 911.,Store at room temperature; do not expose to heat or open flame.,Do not shake the canister before use.,Sit down when using this medication to avoid dizziness or fainting.,Avoid alcohol and erectile dysfunction drugs (e.g., Viagra) while using this medication.
Apply patch to clean, dry, hairless skin on chest, arm, or back; rotate sites daily.,Remove patch after 12-14 hours to prevent tolerance; apply new patch at same time next morning.,Do not use for acute angina; use sublingual nitroglycerin instead.,Avoid alcohol and erectile dysfunction drugs like sildenafil; can cause severe hypotension.,Headache may occur; use acetaminophen or reduce dose; do not stop abruptly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROMIST vs MINITRAN, answered by our medical review team.
NITROMIST is a Nitrate Vasodilator that works by Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing c GMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.. MINITRAN is a Nitrate Vasodilator that works by Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing c GMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROMIST and MINITRAN depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROMIST is: 1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.. The standard adult dose of MINITRAN is: Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROMIST and MINITRAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROMIST is classified as Category C. FDA Pregnancy Category X. Nitroglycerin is contraindicated in pregnancy due to risk of fetal bradycardia and hypotension. First trimester: Risk cannot be ruled out; use only if cle. MINITRAN is classified as Category C. Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trim. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.